维持生物类似药的竞争对药房的好处:使用它或失去它
1Biosimilars Review & Report, Newton, PA.
Journal of managed care & specialty pharmacy
|June 2, 2024
概括
生物仿制药已经为美国卫生系统节省了数十亿美元,但由于折扣偏好,阿达利穆马布生物仿制药的有限市场份额威胁到未来的储蓄. 增加竞争对于降低生物药物成本至关重要.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 生物技术是生物技术.
背景情况:
- 2009年"生物价格竞争与创新法案"旨在通过市场竞争降低生物药物成本.
- 截至2024年4月,15个类别的49种生物仿制药获得了FDA的批准.
- 生物类似竞争已经证明了美国卫生系统的显著成本节约.
研究的目的:
- 评估生物仿制药竞争对医疗保健成本和市场份额的影响.
- 分析影响生物类似药物吸收的因素,特别是对阿达利姆巴.
- 评估对未来生物仿制药开发和节约的潜在威胁.
主要方法:
- 分析到2022年和2023年的成本节省数据.
- 对阿达利穆马布生物类似药的市场份额和配方定位的研究.
- 对付款人和药房福利管理员 (PBM) 关于回扣与折扣的策略的审查.
主要成果:
- 生物类似药在2022年之前为美国卫生系统节省了236亿美元.
- 到2023年,阿达利穆马布生物类似药竞争增加了65亿美元的储蓄,主要是通过折扣.
- 尽管有显著的折扣,但由于对折扣的配方偏好,阿达利穆马布生物仿制药仅占有3%的市场份额.
结论:
- 生物相似竞争已经成功地降低了医疗保健成本.
- 付款人和PBM的以折扣为重点的策略阻碍了生物类似药的市场透.
- 这一趋势可能会危及关键生物类药物管道的未来发展,威胁到未来大幅节省成本.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Drug Control Governance: Regulatory Bodies and Their Impact
153
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
153
Drug Elimination by Renal Route: Tubular Secretion
2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K


